Elicio Therapeutics Inc banner

Elicio Therapeutics Inc
NASDAQ:ELTX

Watchlist Manager
Elicio Therapeutics Inc Logo
Elicio Therapeutics Inc
NASDAQ:ELTX
Watchlist
Price: 10.44 USD -3.51% Market Closed
Market Cap: $182.6m

During the last 3 months Elicio Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 30% over this period (open performance analysis).

The last transaction was made on Aug 12, 2024 by Gkcc, Llc , who bought 20m USD worth of ELTX shares.

Last Transactions:
Gkcc, Llc
$+20m
Venkatesan Jay
$+249.5k
Gkcc, Llc
$+8m
Venkatesan Jay
$+249.5k
Gkcc, Llc
$+6m
Gkcc, Llc
$+7m
Venkatesan Jay
$+1.4k
Venkatesan Jay
$+4k
Venkatesan Jay
$+6.2k
Nissenson Allen
$+240.7
Nissenson Allen
$+852.6
Venkatesan Jay
$+56k
Venkatesan Jay
$+17.1k
Neylan John F.
$-94.3
Venkatesan Jay
$+898.3
Venkatesan Jay
$+3.5k
Venkatesan Jay
$+7.1k
Venkatesan Jay
$+18.7k
Curhan Gregory S
$+948
Rhodes Jennifer J
$-108.8
Goldberg Itzhak
$-10.8k
Goldberg Itzhak
$-13.6k
Goldberg Itzhak
$-13.6k
Goldberg Itzhak
$-13.8k
Neylan John F.
$-152.8
Goldberg Itzhak
$-16.4k
Goldberg Itzhak
$-46.5k
Rhodes Jennifer J
$-189.2
Neylan John F.
$-318.9
Rhodes Jennifer J
$-372
Neylan John F.
$-382.7
Rhodes Jennifer J
$-457.5
View All Transactions

During the last 3 months Elicio Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 30% over this period (open performance analysis).

The last transaction was made on Aug 12, 2024 by Gkcc, Llc , who bought 20m USD worth of ELTX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Elicio Therapeutics Inc
Insider Trading Chart

Elicio Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Elicio Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Elicio Therapeutics Inc
Glance View

Market Cap
182.6m USD
Industry
Pharmaceuticals

Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. The company is headquartered in Boston, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. The company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The firm's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). The company is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The firm is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The firm provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The firm conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

ELTX Intrinsic Value
0.33 USD
Overvaluation 97%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett